相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of68Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring
Nina Zhou et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
Elisa Van Raemdonck et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer
Vincent Walter et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
PET imaging of a 68Ga labeled modified HER2 affibody in breast cancers: from xenografts to patients
Yuping Xu et al.
BRITISH JOURNAL OF RADIOLOGY (2019)
Affibody molecules for molecular imaging and targeted drug delivery in the management of breast cancer
Anindita De et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2018)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary
Antonio C. Wolff et al.
JOURNAL OF ONCOLOGY PRACTICE (2018)
PET of HER2 Expression with a Novel 18FAl Labeled Affibody
Yuping Xu et al.
JOURNAL OF CANCER (2017)
Multiple primary tumours: challenges and approaches, a review
Alexia Vogt et al.
ESMO OPEN (2017)
Affibody molecules as engineered protein drugs
Fredrik Y. Frejd et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2017)
Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry
N. Niikura et al.
ANNALS OF ONCOLOGY (2016)
Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT
Gary A. Ulaner et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients
Mattias Sandstrom et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT
Jens Sorensen et al.
THERANOSTICS (2016)
A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases
Gaetano Aurilio et al.
EUROPEAN JOURNAL OF CANCER (2014)
111In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
Sietske B. M. Gaykema et al.
MOLECULAR IMAGING (2014)
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients
V. Guarneri et al.
ANNALS OF ONCOLOGY (2013)
64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer
Kenji Tamura et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Pilot study of 68Ga-DOTA-F(ab′)2-trastuzumab in patients with breast cancer
Volkan Beylergil et al.
NUCLEAR MEDICINE COMMUNICATIONS (2013)
Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
Linda Sofie Lindstrom et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
HER2 status in a population-derived breast cancer cohort: discordances during tumor progression
Ulla Wilking et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis
Nehmat Houssami et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer
S. van de Ven et al.
CANCER TREATMENT REVIEWS (2011)
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
E. C. Dijkers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules
Richard P. Baum et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Michael M. Schmidt et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Alternative binding proteins:: Affibody binding proteins developed from a small three-helix bundle scaffold
Per-Ake Nygren
FEBS JOURNAL (2008)
Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer
P. H. Cottu et al.
ANNALS OF ONCOLOGY (2008)
Multiple primary tumours in women following breast cancer, 1973-2000
J. S. Raymond et al.
BRITISH JOURNAL OF CANCER (2006)
分享论文
